Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Multiple myeloma: IgG (50 %), IgA (20 %), IgD (few), free light chains (17 %) Serum light chain quantitation Venous blood sample. Provides a rapid, accurate, quantitative measurement of λ and κ ...

It’s possible to live for many years following a relapse of multiple myeloma. Your outlook depends on a number of factors, including the length of time since your last relapse and which ...

A multiple myeloma diagnosis is a life event that can be overwhelming. Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no ...

Darzalex (daratumumab) is used for treating a blood cancer called multiple myeloma. Darzalex may be used to treat multiple myeloma that has never been treated, is relapsed, meaning the cancer ...

Multiple myeloma is a rarer disease than other cancers, such as lung or breast cancer, an expert told CURE®. During the CURE® Educated Patient® Multiple Myeloma Summit, patients asked some questions ...

A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Multiple myeloma is an uncommon cancer affecting plasma cells in the bone marrow. Tumors in the bones and other organs can cause the cells to grow out of control. A complication of this cancer is ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...